November 23, 2021 7:41am

Trading is likely to slow with low volume because it’s Thanksgiving week

Pre-open indications: 4 SELLs, 4 BUY sand 1 Pump (or No Promote)

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

Dow futures are UP +0.05% (+14 points), S&P futures are DOWN -0.02% (-1 points) and NASDAQ futures are DOWN -0.17% (-27 points)

 

U.S. stock futures were mixed and fluctuating down in early morning trading on Tuesday

European stocks were down and retreating 

Asia-Pacific stocks were mixed

 

Henry’omics:

Tuesday is upon us; Thursday is coming fast – after markets put-out poor performance on Monday.

The S&P 500 and Nasdaq (-1.26% or -203.68) fell after a jump in bond yields as the U.S. 10-year Treasury yield climbed by 9 basis points to above 1.62% on Monday.

Breaking News: President Biden said that the administration will tap the Strategic Petroleum Reserve as part of a global effort from energy-consuming nations to calm 2021′s rapid rise in fuel prices.

  • In total the U.S. will release 50 million barrels from the SPR. Of the total 32 million barrels will be an exchange over the next several months, while 18 million barrels will be an acceleration of a previously authorized sale.

 

Economic data Docket: the Philly Fed. Additional data out later in the week includes weekly unemployment claims, a GDP update, personal income, and consumer confidence reads.

 

If you didn’t remember what happen at Monday night’s close, you won’t be prepared for today’s session:

Monday’s evening’s recap: “the sector cratered again as electronics/algorithms usurped investors purchase power, indexes were mixed, some stability not volatility was insured by Powell re-confirmation.” …  https://www.regmedinvestors.com/articles/12194

Q4: November, 3 positive and 13 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL with a Pump or No Promote:

Biostage (BSTG) closed down -$0.30 with 1,141 after Friday’s -$0.39 with 8.625 shares traded, Thursday’s $0.00 with 17 shares traded, Wednesday’s flat with 2,889 shares traded and last Tuesday’s +$0.39 to $2.99 with 2,687 shares traded.

  • Earnings release: Biostage (BSTG) had a net loss of -$800 K, or -$0.80, a $200 K decrease in grant income and a cash position of $2 m—still with NO clinical trial with a 2-year-old IND. Add in some legal negligence ... where its insurance carrier will NOT cover the terminal death suit filed.

What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?

  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation. It’s fake since you can’t make it …

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

SELL into any Strength:

Applied Genetic Technologies (AGTC) closed down -$0.13 to $2.47 after Friday’s -$0.12 to $2.60, Thursday’s +$0.06 to $2.72 and Wednesday’s +$0.29 to $2.66 with a negative -$0.04 or -1.62% aftermarket indication.

Athersys (ATHX) closed up +$0.095 to $1.10 with a positive +$0.02 or +1.82 pre-open indication.

CRISPR Therapeutics (CRSP) closed down again -$1.85 to $80.59 after Friday’s -$0.53 to $82.44, Thursday’s -$3.11 to $82.97, Wednesday’s -$0.50 and last Tuesday’s +$1.50 with a negative -$0.84 or -1.04% pre-open indication.

Intellia Therapeutics (NTLA) closed down again -$4.78 to $124.70 after Friday’s -$5.42 to $129.48, Thursday’s +$0.50 to $134.90, Wednesday’s $134.40 and last Tuesday’s $137.50 with a negative -$0.70 or -0.56% pre-open indication

 

BUY:

Fate Therapeutics (FATE) closed down -$3.52 to $52.45 after Friday’s $55.97, Thursday’s $55.00, Wednesday’s $53.48 and last Tuesday’s $55.49 with a positive +$1.55 or +2.96% pre-open indication.

Regenxbio (RGNX) closed up again +$0.21 to $33.72 after Friday’s +$1.51 to $33.51, Thursday’s +0.51 to $32.00, Wednesday’s -$0.35 to $31.49 and last Tuesday’s $31.84 with a positive +$0.52 or +1.54% pre-open indication.

Vericel (VCEL) closed down -$3.77 to $40.56 after Friday’s $44.33, Thursday’s $42.66, Wednesday’s $42.33 and last Tuesday’s $41.01 with a positive +$1.22 or +3.01% pre-open indication.

Verastem (VSTM) closed down -$0.10 to $2.86 after Friday’s $2.96, Thursday’s $2.99, Wednesday’s $3.15 and last Tuesday’s $3.20 with a positive +$0.08 or +2.80% pre-open indication.

 

 

The BOTTOM LINE: i have NO big hopes for this week ... other than Thursday turkey and NO distance driving ...

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.